NEW YORK (GenomeWeb News) – CytRx subsidiary RXi Pharmaceuticals has licensed short hairpin RNAi technology from Cold Spring Harbor Laboratory, CytRX said today.
 
Under the licensing agreement, RXi purchased a worldwide, non-exclusive license to the technology, which was developed by Cold Spring Harbor’s Gregory Hannon.
 
Hannon is a co-founder and member of RXi’s scientific advisory board.
 
Financial terms of the agreement were not released.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

Two researchers have found that behavioral genetic defenses in criminal cases don't tend to affect outcomes, according to Popular Science.

Researchers report that while host genetics influence the oral microbiome, they don't appear to affect cavity-causing microbes, the Economist says.

Pandas' gut microbiomes change as what they eat changes with the seasons, writes Discover's Inkfish blog.

In PLOS this week: comparative genomic study of malaria-linked macaque parasite, search for apple root reference genes, and more.